Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India
Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro in India, ahead of its competitor Novo Nordisk (NYSE: NVO ). This comes as India, the world’s most populous country, faces rising levels of obesity and diabetes.
Compared to last year’s predictions, Eli Lilly’s Type 2 diabetes drug Mounjaro joined the top 10 list and secured the third spot with projected sales of nearly $20 billion. The three other GLP ...
Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...
Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to ...
Eli Lilly stock has advanced more than 200% ... Demand for tirzepatide has been so high that it immediately landed on the FDA's drug-shortage list following approval and remained there until ...
2don MSN
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback